References of "Krzesinski, Jean-Marie"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailInter-method variability in bone alkaline phosphatase measurement : clinical impact on the management of dialysis patients
CAVALIER, Etienne ULg; Souberbielle, Jean-Claude; GADISSEUR, Romy ULg et al

in Clinical Biochemistry (2014), 47(13-14), 1227-30

BACKGROUND: Bone-specific alkaline phosphatase (BAP) is now recommended to assess bone turnover in hemodialysis (HD) patients. However, little is known about potential variability between methods ... [more ▼]

BACKGROUND: Bone-specific alkaline phosphatase (BAP) is now recommended to assess bone turnover in hemodialysis (HD) patients. However, little is known about potential variability between methods available to measure BAP. METHODS: We measured BAP in 76 HD patients with six different assays (Beckman-Coulter Ostase IRMA, Beckman-Coulter Ostase Access, IDS iSYS Ostase, IDS Ostase enzyme immunoassay, DiaSorin Liaison Ostase and Quidel MicroVue BAP). RESULTS: We observed a high correlation between all the assays ranging from 0.9948 (IDS iSYS vs. IDS EIA) to 0.9215 (DiaSorin Liaison vs. Quidel MicroVue). However, using the regression equations, the equivalent concentration of a Beckman-Coulter Access value of 10μg/L can range from 7.7 to 14.4μg/L and of 20μg/L can range from 16.9 to 27.9μg/L with other assays. According to Beckman-Coulter Access, 13%, 50% and 37% of the patients presented BAP values ≤10, between 10 and 20 and ≥20μg/L, respectively. Discrepancies are observed when other assays are used (concordance from 10 to 100%). CONCLUSIONS: Analytical problems leading to inter-method variation should be overcome to improve the usefulness of this marker in clinical practice. According to correlation results, recalibration of BAP assays is necessary but should not be a major issue. [less ▲]

Detailed reference viewed: 54 (21 ULg)
Full Text
Peer Reviewed
See detailIntérêt des cellules stromales mésenchymateuses en transplantation d’organes solides
Delens, Loic ULg; Jouret, François ULg; DETRY, Olivier ULg et al

in Revue Médicale Suisse (2014), 10

Solid organ transplantation (SOT) currently represents the best therapeutic option in end-stage diseases caused by the irrevocable functional loss of an organ. Still, SOT is associated with immunological ... [more ▼]

Solid organ transplantation (SOT) currently represents the best therapeutic option in end-stage diseases caused by the irrevocable functional loss of an organ. Still, SOT is associated with immunological and non-immunological injuries, whose severity impacts on early functional recovery and long-term survival of the transplant. Current research focuses on the identification of innovative approaches to 1) attenuate ischemia/reperfusion-induced damage, 2) accelerate processes of tissue repair, and 3) induce in fine graft tolerance. Encouraging observations from both preclinical studies and clinical trials suggest that the administration of mesenchymal stromal cells at the time of SOT might be beneficial, as a result of theirs immunomodulatory, anti-inflammatory and regenerative properties. [less ▲]

Detailed reference viewed: 78 (44 ULg)
Full Text
Peer Reviewed
See detailAltération de la fonction rénale chez le patient âgé, comment gérer?
KRZESINSKI, Jean-Marie ULg; DELANAYE, Pierre ULg

in Revue Médicale de Liège (2014), 69(5-6), 287-293

From age 30 onwards, kidney function physiologically decreases although this deterioration cannot yet be called chronic kidney disease. The latter appears in those exposed to cardiovascular risk factors ... [more ▼]

From age 30 onwards, kidney function physiologically decreases although this deterioration cannot yet be called chronic kidney disease. The latter appears in those exposed to cardiovascular risk factors associated with inflammation and oxidative stress. A diffuse atherosclerosis then develops Patients with a decreased glomerular filtration rate, especially below the threshold of 45 ml/min, are characterised by a poor physical heath and by cognitive disorders, leading to frailty. In these conditions, a management strategy to reduce the increased risk of acute kidney injury should be outlined and the need for renal replacement therapy be considered. One must try to maintain the best possible quality of life, promoting in some situations a conservative approach. [less ▲]

Detailed reference viewed: 28 (4 ULg)
Full Text
Peer Reviewed
See detailPrise en charge de l'hypertension artérielle du patient âgé
XHIGNESSE, Patricia ULg; Saint-Remy, Annie ULg; Krzesinski, Jean-Marie ULg

in Revue Médicale de Liège (2014), 69(5-6), 294-300

High blood pressure is very frequent in the elderly; it represents a real threat for the patient’s health and a source of huge costs for the economic system. Systolic hypertension is the most frequent ... [more ▼]

High blood pressure is very frequent in the elderly; it represents a real threat for the patient’s health and a source of huge costs for the economic system. Systolic hypertension is the most frequent form observed in the old, due to large arteries stiffness. Antihypertensive therapy has proven effective to decrease significantly the cardiovascular morbi-mortality and total mortality in this population. A non pharmacological approach is also very useful, but should not be too restrictive. Blood pressure target in patients older than 65 (and, particularly, in octogenarians) is 150/80 mmHg. Blood pressure should be checked in the upright position before changing the drug dosage. The first line therapy in the old should generally be a calcium channel antagonist or a low dose diuretic. [less ▲]

Detailed reference viewed: 78 (9 ULg)
Full Text
See detailY-a-t-il une place pour le placebo dans le traitement de l'hypertension artérielle?
Krzesinski, Jean-Marie ULg

Conference (2014, May 18)

La pression artérielle est très influencée par des stimuli émotionnels ou physiques. Il est donc nécessaire de bien valider le niveau réel de pression artérielle avant de se lancer dans un traitement ... [more ▼]

La pression artérielle est très influencée par des stimuli émotionnels ou physiques. Il est donc nécessaire de bien valider le niveau réel de pression artérielle avant de se lancer dans un traitement actif. Le placebo s’inscrit dans cette mise au point pour garantir l’intérêt réel d’un traitement, en connaître les avantages et les limites. Dans l’hypertension confirmée, l’approche placebo n’a plus réellement sa place au long cours. [less ▲]

Detailed reference viewed: 24 (1 ULg)
Full Text
See detailLes nouvelles directives du contrôle de l'HTA
Krzesinski, Jean-Marie ULg

Conference (2014, May 17)

Successivement au mois de juin 2013 et fin de l’année 2013 sont apparues trois recommandations sur la prise en charge de l’hypertension artérielle. La première relevait de la Société Européenne ... [more ▼]

Successivement au mois de juin 2013 et fin de l’année 2013 sont apparues trois recommandations sur la prise en charge de l’hypertension artérielle. La première relevait de la Société Européenne d’Hypertension et les deux autres de sociétés américaines et internationales. Ces directives accordaient toutes une importante place aux mesures de pression artérielle (PA) en dehors du cabinet de consultation (automesure et mesure ambulatoire de pression sur 24 heures). Elles ont voulu aussi simplifier les cibles de PA à viser qui apparaissent beaucoup moins exigeantes qu’auparavant. Chez les patients âgés, les cibles sont différentes de celles des patients plus jeunes et l’initiation du traitement est d’ailleurs moins rapide. Les bêtabloquants ont été réhabilités dans la stratégie de traitement possible lorsqu’on initie un médicament en présence d’une hypertension artérielle considérée comme nécessitant un médicament antihypertenseur et enfin une stratégie un peu plus claire a été proposée pour l’hypertension artérielle résistante. [less ▲]

Detailed reference viewed: 51 (0 ULg)
Full Text
See detailL'hypertension artérielle
Krzesinski, Jean-Marie ULg

Conference (2014, May 08)

Detailed reference viewed: 72 (3 ULg)
Full Text
Peer Reviewed
See detailCinacalcet treatment at the time of transplantation is associated with a significant risk of delayed graft function in kidney transplant recipients
Jouret, François ULg; WEEKERS, Laurent ULg; GROSCH, Stéphanie ULg et al

in Transplant International (2014, May), 27(S1), 167

The calcium-sensing receptor (CaSR) has been implicated in the ischemia/ reperfusion (I/R) cascade in heart, liver and brain. Renal I/R occurs at the time of transplantation (Tx), with a deleterious ... [more ▼]

The calcium-sensing receptor (CaSR) has been implicated in the ischemia/ reperfusion (I/R) cascade in heart, liver and brain. Renal I/R occurs at the time of transplantation (Tx), with a deleterious impact on early graft function. Here, we retrospectively investigated if the use of cinacalcet, a CaSR agonist, in kidney transplant recipients (KTR) influences early graft recovery. All KTR from 2007 to 2012 in our Academic Hospital were prospectively included in a database. Patients actively treated with cinacalcet on the day of Tx were retrospectively identified from this database and matched with controls on (i) type of donor (living [LD], deceased after brain or circulatory death [DCD]); (ii) cold ischemic time (CIT) ` 1 h; (iii) residual diuresis (` 500 ml); and (iv) donor age (` 5 years). Delayed graft function (DGF) was defined as dialysis requirement after Tx. Baseline characteristics were compared between groups with student’s t-test or Chi-2 as appropriate. The endpoint was the percentage of DGF in both groups. Among 337 KTR, 36 (10.7%) were treated with cinacalcet at Tx. Control group included 61 patients. Characteristics of patients and donors are summarized in the table. DGF occurred in 42 and 23% of cinacalcet-treated and control groups, respectively (p = 0.05). These retro- spective observations suggest that CaSR activation at the time of Tx impairs early graft recovery. [less ▲]

Detailed reference viewed: 88 (19 ULg)
Full Text
See detailComportements à risque et maladies cardio-vasculaires. Comment infléchir le cours des choses?
Etienne, Anne-Marie ULg; Krzesinski, Jean-Marie ULg; André, Jean-François

Scientific conference (2014, April 01)

«Comportements à risques et maladies cardio-vasculaires, comment infléchir le cours des choses ?» Entre recommandations, croyances et attitudes des médecins, croyances, attitudes et vécu des patients ... [more ▼]

«Comportements à risques et maladies cardio-vasculaires, comment infléchir le cours des choses ?» Entre recommandations, croyances et attitudes des médecins, croyances, attitudes et vécu des patients, comment améliorer la prévention dans le domaine cardio-vasculaire ? [less ▲]

Detailed reference viewed: 57 (18 ULg)
Full Text
See detailComportements à risques et maladies cardio-vasculaires, comment infléchir le cours des choses?
Krzesinski, Jean-Marie ULg; andre, Jean-François

Conference (2014, April 01)

Entre recommandations, croyances et attitudes des médecins, croyances, attitudes et vécu des patients, comment améliorer la prévention dans le domaine cardio-vasculaire?

Detailed reference viewed: 24 (6 ULg)
Full Text
See detailTraitement antihypertenseur : quelles sont les meilleures associations?
Krzesinski, Jean-Marie ULg

Conference (2014, February 22)

Stratégie du traitement de l’HTA en 2014: toujours basée sur le calcul du risque CV. L’HTA, tueur silencieux, est généralement associée à de nombreux autres facteurs de risque CV. Il faut préciser le ... [more ▼]

Stratégie du traitement de l’HTA en 2014: toujours basée sur le calcul du risque CV. L’HTA, tueur silencieux, est généralement associée à de nombreux autres facteurs de risque CV. Il faut préciser le niveau de risque CV en tenant compte de la valeur de PA et des autres F.R. pour décider le moment et le type de traitement ! [less ▲]

Detailed reference viewed: 42 (1 ULg)
Peer Reviewed
See detailUn cas particulier d'amyloïdose AA
MILICEVIC, Martina ULg; GROSCH, Stéphanie ULg; Krzesinski, Jean-Marie ULg et al

Conference (2014, January 22)

Detailed reference viewed: 23 (7 ULg)
Full Text
Peer Reviewed
See detailDetection of decreased glomerular filtration rate in intensive care units: serum cystatin C versus serum creatinine
DELANAYE, Pierre ULg; CAVALIER, Etienne ULg; Morel, Jérôme et al

in BMC Nephrology (2014), 15(9), 1471-2369

Detailed reference viewed: 26 (9 ULg)
Full Text
Peer Reviewed
See detailCockcroft&Gault and CKD-EPI equations: are these equations concordant to adjust drug dosage?
BOUQUEGNEAU, Antoine ULg; Vidal-Petito, E; Vrtovsnik, F et al

Poster (2014)

Detailed reference viewed: 18 (3 ULg)